Citations

Showing 10 of 108162 citations.

Stratified performance on the Test of Memory Malingering (TOMM) is associated with differential responding on the Personality Assessment Inventory (PAI)
Whiteside, Douglas M. , Hunt, Isaac J., Choate, Alyssa, Caraher, Kristen , Basso, Michael R. , Whiteside, Douglas , Choate, Alyssa Zwicker

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | November 27, 2019 | Volume: 42 | Issue: 2 | Pages: 131-141

10.1080/13803395.2019.1695749 | PMID 31771455 Get It

Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future
Geiersbach, Katherine B. , Meyer, Reid G., Sill, Daniel R, Mounajjed, Taofic, Chen, Beiyun, Sukov, William R. , Jenkins, Robert B. , Geiersbach, Katherine

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 38 | Issue: 2 | Pages: 175-176

10.1200/jco.19.02482 | PMID 31770062 Get It

Regulation and adaptation of endocrine axes at high altitude
Keenan, Daniel M., Hefti, Jacqueline Pichler , Veldhuis, Johannes D. , Wolff, Michael von

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | November 26, 2019 | Volume: 318 | Issue: 2 | Pages: E297-E309

10.1152/ajpendo.00243.2019 | PMID 31770013 Get It

As a model of extreme conditions, eight healthy women, part of a 40-member Nepal mountain-climbing expedition, were monitored for dynamic endocrine adaptations. Endocrine measurements were made at frequent intervals over a 6–10-h period at four altitudes: 450 m, 4,800 m (base camp), 6,050 m, and again at 4,800 m (on descent) after an acclimatization (A) period (4,800 mA). Quantified hormones were growth hormone (GH), prolactin (PROL), cortisol (Cort), thyroid-stimulating hormone (TSH), and free thyroxine. These hormones are important to the anabolic/catabolic balance of the body, and are vital to growth, homeostasis, hypothalamic inhibition, regulation of stress, and metabolism. A key secondary question was the degree to which acclimatization can stabilize hormonal disruption. On the basis of statistical false discovery rates, the present analyses unveil marked adaptive changes in the thyroid axis at the level of pulsatile secretion of the pituitary hormone TSH and its downstream product, free thyroxine; strong effects on the mass of GH, TSH, Cort, and PROL secretion per burst; and prominent pulsatile frequency disruption and recovery for PROL and Cort. Because pulsatility changes reflect de facto perturbations in hypothalamo-pituitary control mechanisms, the present data introduce the concept of both frequency- and amplitude-dependent adaptive control of brain-pituitary neuroendocrine signals under conditions of extreme altitude exertion and exposure.
Secondary prevention after coronary artery bypass grafting saves lives: a golden opportunity often wasted
López-Jiménez, Francisco , Lopez-Jimenez, Francisco , Gersh, Bernard J.

Mayo Clinic

European Heart Journal | November 26, 2019 | Volume: 41 | Issue: 17 | Pages: 1662-1664

10.1093/eurheartj/ehz855 | PMID 31800026 Get It

The bicuspid aortic valve raphe: an evolving structure
Enriquez‐Sarano, Maurice , Yang, Li-Tan, Enriquez-Sarano, Maurice , Yang, Li‐Tan , Michelena, Héctor I.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | November 26, 2019 | Volume: 21 | Issue: 5 | Pages: 590-590

10.1093/ehjci/jez294 | PMID 31808504 Get It

Osteoporosis-related Vertebral Fragility Fractures
Robinson, William A. , Carlson, Bayard C. , Poppendeck, Heidi, Wanderman, Nathan , Bunta, Andrew D., Murphy, Sarah , Sietsema, Debra L. , Daffner, Scott D. , Watts, Nelson B. , Tosi, Laura L. , Anderson, Paul A. , Freedman, Brett A. , Wanderman, Nathan R, Edwards, Beatrice J.

Mayo Clinic

Spine | November 26, 2019 | Volume: 45 | Issue: 8 | Pages: E430-E438

10.1097/brs.0000000000003324 | PMID 31770343 Get It

Study Design. Retrospective cohort study of the Own the Bone database which is a fracture liaison service designed to improve recognition and treatment of osteoporosis. Objective. To use the Own the Bone (OTB) database to 1) examine the specific demographics of patients presenting with a low-energy clinical vertebral fracture (VFX) and 2) compare demographic and fracture-specific risk factors between patients with clinical VFX versus patients with nonvertebral low-energy fracture (NVFX). Summary of Background Data. Large database studies have described risk factors for developing VFX. It is well described that a history of previous VFX portends an increased risk of future VFX. Few studies have reported cohorts from a fracture liaison service such as the OTB initiative. Methods. 35,039 unique cases of fragility fracture occurred between 2009 and 2016 and were included in analysis. VFX accounted for 3395 (9.9%) of the presenting fractures at OTB enrollment. The demographics, lifestyle factors, medication use, and fracture-specific data for patients in the OTB registry with vertebral fractures were summarized and then statistically compared to those with nonvertebral fragility fractures. Results. The majority of VFX patients were Caucasian, postmenopausal women (74.4%). There was an increased likelihood of presenting with a vertebral fracture in patients who sustained a previous VFX after the age of 50, while patients who sustained a prior nonvertebral fracture (NVFX) were more likely to present with a subsequent NVFX. After controlling for patients with a history of fracture after the age of 50, VFX patients (vs. NVFX) were more likely to be age 70–79, class 1 obesity, with a history of taking anti-osteoporotic prescription medications. Conclusions. Multiple factors were associated with a significantly increased risk of VFX compared with NVFX. Understanding the risk factors unique to fragility VFX is a critical component for targeting “at-risk” patients and preventing future osteoporosis-related fractures and their consequences. Level of Evidence: 4
Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)
Baretella, Oliver , Blaise, Gilbert, Bond, Richard A. , Cai, Yin , Chan, C K, Chataigneau, Thierry, Chen, M., Chen, Hui , Cheng, Yanhua, Clément, Denis, Cohen, Richard A. , Collis, Michael J., Detremmerie, Charlotte Marie Simonne, Félétou, Michel, Flavahan, Nicolas, Gao, Yuansheng, Guo, Yumeng , Hoeffner, U., Houston, Donald S., Huang, Ianto Boscheng, Huang, Yü , Iliano, Stephane, Junquéro, Didier, Katušić, Zvonimir S. , Komori, Kimihiro , Lee, Mary Y. K. , Leung, Susan W.S. , Li, Zhuo-ming, Liang, Sophie Chaofan, Liu, J, Lüscher, Thomas F. , Michel, Frederic, Miller, Virginia M. , Mombouli, Jean-Vivien, Morrison, Keith , Muldoon, Sheila M., O’Rourke, Steve, Perrault, Louis P. , Quignard, Jean‐François , Rusch, Nancy J. , Sánchez‐Ferrer, Carlos F. , Shen, Kaikai , Shi, Yi , Song, Erfei , Sun, Kiwi W.Y., Tang, Eva Hoi Ching, Tuncer, Meral , Ende, Romana van den, Vedernikov, Yuri P., Verbeuren, Tony J., Webb, Clinton, Wong, Kenneth H.K., Xu, Cheng , Yang, Kangmin , Zellers, Thomas M. , Zhao, Yingzi , Zou, Qian , fellows, on behalf of Professor Paul M. Vanhoutte’s former, Boulanger, Chantal M. , Collis, Michael, Danser, A.H. Jan , Mey, Jo G. R. De , Duprez, Daniel , Huang, Ianto Bosheng , Michel, Frederic, Schini‐Kerth, Valérie B. , Shi, Yi, Taddei, Stefano , Tang, Eva H.C., Weigert, André Luiz Loureiro , Wong, Kenneth K. H., Ying, Fan, Shimokawa, Hiroaki , fellows, on behalf of Professor Paul M. Vanhoutte’s former

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 39 | Issue: 12 | Pages: 2445-2447

10.1161/atvbaha.119.313461 | PMID 31770032 Get It

Effect of paclitaxel and carboplatin on tumor-reactive T cells and the efficacy of PD-1 blockade.
Yan, Yiyi , Dronca, Roxana , Markovic, Svetomir, Liu, Xin, Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 65-65

10.1200/jco.2017.35.7_suppl.65 Get It

65 Background: The addition of chemotherapy to immune checkpoint inhibitors has been explored clinically in solid tumors in order to overcome one of the challenges of immunotherapy: clinical outcomes are variable, with only a subset of patients achieving durable responses. Further understanding of the immunoregulatory mechanisms of chemotherapy in the setting of immunotherapy is crucial for the development of optimal combinatorial chemo-immunotherapeutic strategies to improve clinical outcomes in patients with advanced cancer. Methods: Metastatic melanoma (MM) patients who failed anti-PD-1 single therapy were subsequently treated with paclitaxel and carboplatin in addition to PD-1 blockade. Using peripheral blood (PB) from MM patients and healthy donor, the phenotypic and functional changes in T cells induced by chemotherapy, in the setting of PD-1 blockade, were examined. Results: Paclitaxel and carboplatin, in combination with PD-1 blockade, were able to induce significant clinical responses in a subset of MM patients who were resistant to anti-PD-1 therapy alone. In patients who responded to this combination, a subset of tumor-reactive effector T cells (CD8+CD11a+PD1+GranzymeB+) survived the treatment, with increased frequency after the addition of chemotherapy. This T cell population preserved its effector phenotype, although ongoing PD-1 blockade was needed to improve its anti-tumor activity. In vitro experiments, using CD8+CD11a+PD1+GranzymeB+isolated from healthy donor PB, also demonstrated its ability to survive chemotherapy treatment. In addition, after cultured with chemotherapy, this T cell subset demonstrated higher cytotoxic T cell functions as well as increased chemotherapy efflux. Conclusions: Chemotherapy regulates a subset of tumor-reactive effector T cells (CD8+CD11a+PD1+GranzymeB+) and increases clinical efficacy of PD-1 blockade. This novel effector T cell population underlies the key cellular and molecular immunoregulatory mechanisms of chemotherapy. It serves as a meaningful marker to measure these collaborative effects and to develop the optimal chemo-immunotherapy strategy to improve clinical responses to current immune checkpoint blocking agents.
Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.
Tine, Brian Andrew Van, Hu, James , Schuetze, Scott M. , Attia, Steven , Priebat, Dennis A., Okuno, Scott H. , Riedel, Richard F. , Movva, Sujana , Baker, Laurence H. , Maki, Robert G. , Patel, Shreyaskumar , Tawbi, Hussein, Maki, Robert G , Riedel, Richard F , Burgess, Melissa , Roszik, Jason , D'Angelo, Sandra P , Davis, Lara E. , Reed, Damon R. , Reinke, Denise K. , Butterfield, Lisa Helene

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 60-60

10.1200/jco.2017.35.7_suppl.60 Get It

60 Background: The activity of the anti-PD-1 antibody P in pts with advanced STS was evaluated in a prospective multicenter Phase II study conducted by the Sarcoma Alliance for Research through Collaboration (SARC). SARC028 enrolled 40 patients with advanced soft tissue sarcoma. Pembro had an ORR of 19% and PFS rate at 12 weeks of 55%, suggesting clinical activity. We investigated biomarkers of response to P. Methods: The primary endpoint was Objective Response Rate (ORR) by RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival, and biomarkers of response in blood and tumor. Pre- and on-treatment biopsies were required and obtained from over 90% and 72% of pts respectively. Serum was obtained from all pts at baseline and at multiple time points on therapy (pre-, week 8, and every 12 weeks). Sera were examined for candidate circulating biomarkers by Affymetrix Luminex platform array, including PD-L2. To determine whether there is a statistically significant difference between different conditions, we used Mann-Whitney and two-tailed t tests. Log-rank p-values in Kaplan-Meier survival analyses were calculated using the "survival" R package. Results: Forty pts with STS were enrolled into 4 cohorts (10 each) based on histological subtype including undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (LPS), synovial sarcoma (SS), and leiomyosarcoma (LMS). 4 pts with UPS, 2 pts with LPS, and one pt with SS achieved a response. Six of seven responses were durable at the time of this analysis. Circulating levels at baseline or after therapy of PD-1, PD-L1, 4-1BB, IDO, BTLA, CTLA-4, LAG-3, and TIM-3 did not correlate with outcome. However, pre-treatment and week 8 PD-L2 levels correlated best with clinical outcome: high PD-L2 levels were associated with better PFS (p=0.019) in STS. Conclusions: P has clinical activity in specific histologic subtypes of STS, namely UPS and LPS. Pre-treatment circulating PD-L2 levels correlated with progression-free survival and is a novel and promising predictor of improved clinical outcome of PD-1 therapy in STS.
Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma.
Dronca, Roxana , Harrington, Susan M. , Jegapragasan, Mithulan , Kottschade, Lisa A. , Nevala, Wendy K. , Enninga, Elizabeth Ann L. , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 4-4

10.1200/jco.2017.35.7_suppl.4 Get It

4 Background: Membrane expression of PD-L1 on tumor cells is associated with poor survival in patients with advanced malignancies including metastatic melanoma (MM). In addition, tumor-associated PD-L1 has been proposed as a predictor of response to anti-PD-1 therapy, although responses are observed in some cases of PD-L1 negative MM. We hypothesize that tumor-derived PD-L1 has additional systemic effects through the release of biologically active soluble forms of PD-L1 (sPD-L1) into the circulation, which further impedes the anti-tumor immune response and contributes to poor clinical outcomes in MM. Methods: We developed a sPD-L1 ELISA and biochemically confirmed the identity of the detected protein. We measured the levels of sPD-L1 in 276 patients with MM enrolled on 3 clinical trials who had stored pre-treatment plasma samples and 37 healthy volunteers (HV) undergoing blood donation at Mayo Clinic. We also measured sPD-L1 in baseline samples from 38 MM patients treated with anti-PD1 (pembrolizumab) 2 mg/kg every 3 weeks. ROC analysis was used to compute sPD-L1 concentration cut-off value and Wald test was used to asses the difference of overall survival (OS) in patients with low versus high sPD-L1 concentration. Results: We found that sPD-L1 levels were significantly elevated in MM patients compared with HV (p=0.0011). Mean sPD-L1 level in MM was 1.73 ng/mL (range: 0.13-18.29) compared with 0.77 ng/mL (range: 0.11–6.02) for HV. Patients with higher levels (>0.293 ng/mL) had a median OS of 11.3 months compared to 14.8 months for patients with sPD-L1 level ≤ 0.293 ng/mL (p=0.040). Similarly to tumor-related PD-L1 findings, patients who had clinical benefit (OR/PR/SD) after 4 cycles of anti-PD1 had higher sPD-L1 levels at baseline (2.1 vs. 1.1 ng/mL). Conclusions: To our knowledge, our study is the first to report a correlation of sPD-L1 with MM patient outcome, although a larger study is needed to establish the utility of sPD-L1 as an independent prognostic and possibly predictive biomarker.